Due to the rarity of p.L747P mutation in NSCLC, its response to different types of EGFR TKIs is unclear and controversial, and most studies suggested that it mediated intrinsic resistance to 1G TKIs while increasing the sensitivity to afatinib (30–37). Here, EGFR is linked to non-small cell lung carcinoma.